Bruker推出新型ultrafleXtreme MALDI-TOF/TOF质谱

 


Bruker推出新型ultrafleXtreme MALDI-TOF/TOF质谱 最新应用成果远远超过传统界限

　　温哥华，不列颠哥伦比亚省--2012年5月21日—在ASMS 2012展会上，Bruker公司宣布推出新型ultrafleXtreme™ MALDI TOF/TOF质谱系统。凭借增强的分析性能和全新的功能，该系统使得Bruker公司在顶尖质谱产品市场的领导地位得到了显著提高，同时开拓了MALDI TOF/TOF传统的应用领域，新领域包括分子组织学、糖蛋白和生物制药分析领域。

新型ultrafleXtreme™ MALDI TOF/TOF质谱系统

　　质谱成像(MSI)是目前被大家公认的领导技术，下一代ultrafleXtreme系统采用Bruker专利smartbeam™激光技术，激光频率可达2 kHz，检测蛋白的图像分辨率为20µm。这一发展标志了smartbeam™激光技术的又一里程碑，该技术专为Bruker无以伦比的MALDI质谱技术所开发设计。

　　目前，针对大体积组织样品中的生物标志物发现的分析速度，已达到了创纪录的高速，Bruker公司新型ImageID™工作流程显著开拓了分子组织学的开发潜能。专利的ImageID™能够提供完全集成的工作流程，科学家可得到集成的蛋白分布和鉴定的组织图。使用ImageID™工作流程能够完成100多个蛋白的表征分析，在单一的软件环境下，进行连续组织切片流程的同时可平行产生互补的数据集。ImageID™能够鉴定从图像测量所获取的约80%的肽段，并且能够鉴定那些高分子量的蛋白。该方法首次实现了分析固定组织(FFPE)，能够使分子组织学应用于收集大量的归档临床样品，从而打开在癌症研究中生物标志物数据的潜在宝箱。

　　ultrafleXtreme质谱配备专利的自上而下的T³-Sequencing测序技术能够揭示蛋白终端修饰、翻译后修饰(PTMs)以及序列杂质，引领了生物制药表征分析的行业潮流。Bruker新型ultrafleXtreme质谱平台的高分辨率完整生物分子分析，快速扩展了其生物制剂用户。新型的ultrafleXtreme™ MALDI TOF/TOF质谱跨越了MALDI与电喷雾电离的传统界限，能够在30,000的高分辨率下检测复合完整蛋白离子，还可获得30 kDa蛋白的同位素信息，大蛋白分子质量分布的质量精确度优于15ppm。采用革新的ultrafleXtrem FlashDetector™和DHAP基质，所得到的完整蛋白生物分析能力代表了进行生物制剂开发、研究和质量控制模式的改变。

　　通过Bruker最新的GlycoQuest™搜索引擎工具能够前所未有的轻松找回候选多糖结构，使每一位生物学家都能够成为糖蛋白结构鉴定的专家。使得ultrafleXtreme质谱在生物制药行业和生命科学研究领域的应用得到了进一步的提高。

　　Bruker Daltonics公司生物制药市场经理Laura Main博士评论说：“MALDI质谱分析能够快速简单的得出精确完整生物分子数据，为我们的生物制药用户提供了真正完整的糖蛋白结构图像。”

　　关于Bruker公司

　　Bruker公司(NASDAQ: BRKR)是一家提供高性能科学仪器和解决方案的领先供应商，该产品可应用于分子和材料领域以及工业的应用分析中。欲了解更多信息，请登录www.bruker.com。

Bruker Announces the New ultrafleXtreme MALDI-TOF/TOF Mass Spectrometer for Novel Applications Achievements Far Beyond Traditional Boundaries

VANCOUVER, British Columbia--(BUSINESS WIRE)--May. 21, 2012-- At ASMS 2012, Bruker announces the launch of the new ultrafleXtreme™ MALDI TOF/TOF system. Bruker's market leading, top of the range product has been significantly enhanced to offer both increased analytical power and entirely new functionality, extending the applications envelope of MALDI TOF/TOF far beyond the conventional concepts of what's possible in molecular histology, glycoprotein and biopharmaceuticals analysis.

Already the acknowledged leader in Mass Spectrometry Imaging (MSI), the next-generation ultrafleXtreme system incorporates the Bruker patented smartbeam™laser, now with up to 2 kHz repetition rate with true-pixel image resolution at 20µm for proteins. This development marks a new milestone in the pioneering smartbeamlaser technology, designed and manufactured exclusively by Bruker for unmatched performance in MALDI mass spectrometry.

While biomarker discovery in large tissue-sample cohorts can now be achieved at record high speed, Bruker has also significantly extended the discovery potential of Molecular Histology with the new ImageID™ workflow. The proprietary ImageIDworkflow is a fully-integrated process to provide scientists with integrated tissue maps for both protein distribution and identification. More than 100 proteins are typically characterized by the ImageID workflow, where consecutive histological sections are processed in parallel to generate complementary datasets in a single software environment for comprehensive analysis. ImageID yields identifications of approximately 80% of all peptides observed in imaging measurements, also those derived from high molecular weight proteins. For the first time, the method can access fixed (FFPE) tissue, allowing molecular histology to be applied to vast collections of archived clinical samples to unlock a potential treasure chest of biomarker data in cancer studies.

The ultrafleXtreme has also become the industry trendsetter in tools for biopharmaceutical characterization with patented Top-Down T³-Sequencing for revealing terminal modifications, post-translational modifications (PTMs) and sequence impurities. Bruker now presents its rapidly expanding biologics customer base with high resolution intact biomolecule analysis on the new ultrafleXtreme platform. The new MALDI-TOF/TOF system leaps across the conventional boundary between MALDI and electrospray ionization by generating multiply-charged intact protein ions for measurements with mass resolution of greater than 30,000, which can yield isotopic information for 30 kDa proteins, and larger protein molecular weight assignments with better than 15 ppm mass accuracy. Achieved using the new ultrafleXtreme FlashDetector™ and DHAP matrix innovations, this intact protein bioanalytical ability represents a paradigm change for biologics discovery, development and QC.

The ultrafleXtreme's utility for the biopharmaceutical industry and life-science research is further enhanced by Bruker's new GlycoQuest™ glycan search engine which retrieves glycan structure candidates with unprecedented ease, enabling expert full glycoprotein structure elucidation for every molecular biologist.

"Precise intact biomolecule data at the speed and simplicity of MALDI analysis with full glyco-structure reporting really completes the picture for our biopharma customers," commented Dr. Laura Main, Bruker Daltonics' Biopharmaceutical Market Manager.

About Bruker Corporation

Bruker Corporation (NASDAQ: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information, please visithttp://www.bruker.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50283564&lang=en

Source: Bruker Corporation

Bruker Daltonics
Paula Audet, +1 978-663-3660 ext. 1365
Marketing Communications Specialist
pfa@bdal.com